- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05809791
Molar Incisor Hypomineralization and Hypomineralized Second Primary Molars
May 13, 2025 updated by: IRCCS Burlo Garofolo
Prevalence and Clinical Characteristics of Molar Incisor Hypomineralization (MIH) and Hypomineralized Second Primary Molars (HSPM) Among Italian, Spanish and Turkish Children: a Multicenter Epidemiological Study
Molar and Incisor Hypomineralization (MIH) is a qualitative developmental defect of the dental enamel with a multifactorial aetiology defined in 2001 as an "hypomineralization of systemic origin affecting one or more permanent molars, usually first permanent molars (FPMs) with or without the involvement of one or more affected permanent incisors".
Due to its porous structure with an altered prism organization and an increased content of proteins, the hypomineralized enamel has reduced mechanical properties and a lower refractive index in comparison to the sound enamel.
MIH is associated to a large number of objective and subjective problems as an altered aesthetics, an increased risk of plaque accumulation, caries and/or post-eruptive breakdown, reduced retention rates of adhesive materials, hypersensitivity and difficulty in anesthetizing the affected teeth that make its management a challenging condition.
MIH is a very widespread pathology with a worldwide prevalence ranging from 2.8 to 44% and a global average prevalence of 13.1% with significant geographical differences.
In 2015, the number of global prevalent cases was estimated at 878 million people with a percentage of needing-care cases of 27.4% (in mean 240 million prevalent cases).
In Europe, MIH prevalence rates between 3.6 to 25%.
Regarding Italy, a limited number of prevalence studies are available.
Recently, literature reports that the presence of MIH-like lesions in primary dentition, especially on second primary molars, may be a predictive factor for developing MIH in permanent dentition.
However, the absence of this defect called Hypomineralized Second Primary Molars (HSPM) does not rule out MIH development.
The early diagnosis of HSPM is very useful to early diagnose MIH and reduce its care burden.
The reported HSPM global prevalence rate ranges from 0 to 21.8% with a global average about 7.88%.
MIH and HSPM are both very widespread pathologies affecting an increasing number of children worldwide and represent a significant problem in pediatric dentistry.
The aim of this study is to estimate the prevalence of MIH in Italian (Trieste), Spanish (Huesca, Zaragoza) and Turkish (Istanbul) children.
The hypothesis is that the estimated prevalence of MIH may be in line with that reported in literature and that the presence of HSPM in primary dentition may be associated with MIH development in permanent dentition.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
97
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Subjects will be selected among patients attending the involved Dental Clinics according to the following criteria
Description
Inclusion Criteria:
- Age: 6-16 years;
- Signature of the informed consent to the study by patients' parents or by their legal guardians
Exclusion Criteria:
- Fluorosis, white spots, amelogenesis imperfecta, hypoplasia or other dental enamel defects in differential diagnosis with MIH and HSPM;
- Patients not sufficiently cooperative;
- Children with orthodontic devices hiding the teeth to consider
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MIH prevalence rate
Time Frame: At baseline (day one)
|
Prevalence of the condition in the populations studied
|
At baseline (day one)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Description of MIH clinical characteristics
Time Frame: At baseline (day one)
|
Description of the clinical characteristics of MIH, evaluated by questionnaire
|
At baseline (day one)
|
|
Frequency of the most frequently affected teeth
Time Frame: At baseline (day one)
|
Evaluated by questionnaire
|
At baseline (day one)
|
|
Association between HSPM and MIH development
Time Frame: At baseline (day one)
|
Evaluated by questionnaire
|
At baseline (day one)
|
|
Association between MIH/HSPM and presence of caries
Time Frame: At baseline (day one)
|
Evaluated by questionnaire
|
At baseline (day one)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Milena Cadenaro, MD, IRCCS Materno Infantile Burlo Garofolo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 2, 2021
Primary Completion (Actual)
December 31, 2024
Study Completion (Actual)
December 31, 2024
Study Registration Dates
First Submitted
March 28, 2023
First Submitted That Met QC Criteria
April 11, 2023
First Posted (Actual)
April 12, 2023
Study Record Updates
Last Update Posted (Actual)
May 16, 2025
Last Update Submitted That Met QC Criteria
May 13, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC 11/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Molar Incisor Hypomineralization
-
Cairo UniversityCompletedHypomineralization of Enamel | Hypomineralization Molar IncisorEgypt
-
Cairo UniversityNot yet recruitingMolar Incisor Hypomineralization | Hypomineralization of Enamel | Hypomineralization Molar Incisor | Molar Incisor Hypomineralisation
-
University of Nove de JulhoCompletedHypomineralization Molar IncisorBrazil
-
University of Nove de JulhoRecruiting
-
Marmara UniversityNot yet recruitingMolar-Incisor Hypomineralization
-
Marmara UniversityNot yet recruitingMolar-Incisor Hypomineralization
-
Cairo UniversityNot yet recruitingEffect of Nano Hydroxy Apatite Varnish and Potassium Nitrate Gel on the MIH-affected Permanent TeethMolar Incisor Hypomineralisation
-
University of Nove de JulhoNot yet recruitingHypomineralization Molar Incisor | Hypersensitivity Dentin
-
Recep Tayyip Erdogan University Training and Research...CompletedPeridontal Disease | Molar-Incisor HypomineralizationTurkey
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedMolar Incisor HypomineralisationUnited Kingdom